Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device

David S. Baskin; Martyn A. Sharpe; Lisa Nguyen; Santosh A. Helekar

doi:10.3389/fonc.2021.708017

Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device

David S. Baskin, Martyn A. Sharpe, Lisa Nguyen, Santosh A. Helekar

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Alternating electric field therapy has been approved for glioblastoma (GBM). We have preclinical evidence for anticancer effects in GBM cell cultures and mouse xenografts with an oscillating magnetic field (OMF) generating device. Here we report OMF treatment of end-stage recurrent glioblastoma in a 53-year-old man who had undergone radical surgical excision and chemoradiotherapy, and experimental gene therapy for a left frontal tumor. He experienced tumor recurrence and progressive enlargement with leptomeningeal involvement. OMF for 5 weeks was well tolerated, with 31% reduction of contrast-enhanced tumor volume and reduction in abnormal T2-weighted Fluid-Attenuated Inversion Recovery volume. Tumor shrinkage appeared to correlate with treatment dose. These findings suggest a powerful new noninvasive therapy for glioblastoma.

Original language	English (US)
Article number	708017
Pages (from-to)	708017
Journal	Frontiers in Oncology
Volume	11
DOIs	https://doi.org/10.3389/fonc.2021.708017
State	Published - Jul 22 2021

Keywords

compassionate use treatment
contrast enhanced tumor
magnetic resonance imaging
oscillating magnetic fields
radiation-type tumor necrosis 2

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2021.708017

Cite this

@article{87201b1c3fcf410688d902fa753f7b7a,

title = "Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device",

abstract = "Alternating electric field therapy has been approved for glioblastoma (GBM). We have preclinical evidence for anticancer effects in GBM cell cultures and mouse xenografts with an oscillating magnetic field (OMF) generating device. Here we report OMF treatment of end-stage recurrent glioblastoma in a 53-year-old man who had undergone radical surgical excision and chemoradiotherapy, and experimental gene therapy for a left frontal tumor. He experienced tumor recurrence and progressive enlargement with leptomeningeal involvement. OMF for 5 weeks was well tolerated, with 31% reduction of contrast-enhanced tumor volume and reduction in abnormal T2-weighted Fluid-Attenuated Inversion Recovery volume. Tumor shrinkage appeared to correlate with treatment dose. These findings suggest a powerful new noninvasive therapy for glioblastoma.",

keywords = "compassionate use treatment, contrast enhanced tumor, magnetic resonance imaging, oscillating magnetic fields, radiation-type tumor necrosis 2",

author = "Baskin, {David S.} and Sharpe, {Martyn A.} and Lisa Nguyen and Helekar, {Santosh A.}",

note = "Funding Information: This work was supported by a grant from the Translational Research Initiative of the Houston Methodist Research Institute to SH and DB, and by Donna and Kenneth Peak, the Kenneth R. Peak Foundation, the John S. Dunn Foundation, the Taub Foundation, the Blanche Green Fund of the Pauline Sterne Wolff Memorial Foundation, the Kelly Kicking Cancer Foundation, the Gary and Marlee Swarz Foundation, the Methodist Hospital Foundation, and the Veralan Foundation. The John S. Dunn Foundation also supports the Distinguished Professorship of MS. Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Baskin, Sharpe, Nguyen and Helekar.",

year = "2021",

month = jul,

day = "22",

doi = "10.3389/fonc.2021.708017",

language = "English (US)",

volume = "11",

pages = "708017",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Case Report

T2 - End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device

AU - Baskin, David S.

AU - Sharpe, Martyn A.

AU - Nguyen, Lisa

AU - Helekar, Santosh A.

N1 - Funding Information: This work was supported by a grant from the Translational Research Initiative of the Houston Methodist Research Institute to SH and DB, and by Donna and Kenneth Peak, the Kenneth R. Peak Foundation, the John S. Dunn Foundation, the Taub Foundation, the Blanche Green Fund of the Pauline Sterne Wolff Memorial Foundation, the Kelly Kicking Cancer Foundation, the Gary and Marlee Swarz Foundation, the Methodist Hospital Foundation, and the Veralan Foundation. The John S. Dunn Foundation also supports the Distinguished Professorship of MS. Publisher Copyright: © Copyright © 2021 Baskin, Sharpe, Nguyen and Helekar.

PY - 2021/7/22

Y1 - 2021/7/22

N2 - Alternating electric field therapy has been approved for glioblastoma (GBM). We have preclinical evidence for anticancer effects in GBM cell cultures and mouse xenografts with an oscillating magnetic field (OMF) generating device. Here we report OMF treatment of end-stage recurrent glioblastoma in a 53-year-old man who had undergone radical surgical excision and chemoradiotherapy, and experimental gene therapy for a left frontal tumor. He experienced tumor recurrence and progressive enlargement with leptomeningeal involvement. OMF for 5 weeks was well tolerated, with 31% reduction of contrast-enhanced tumor volume and reduction in abnormal T2-weighted Fluid-Attenuated Inversion Recovery volume. Tumor shrinkage appeared to correlate with treatment dose. These findings suggest a powerful new noninvasive therapy for glioblastoma.

AB - Alternating electric field therapy has been approved for glioblastoma (GBM). We have preclinical evidence for anticancer effects in GBM cell cultures and mouse xenografts with an oscillating magnetic field (OMF) generating device. Here we report OMF treatment of end-stage recurrent glioblastoma in a 53-year-old man who had undergone radical surgical excision and chemoradiotherapy, and experimental gene therapy for a left frontal tumor. He experienced tumor recurrence and progressive enlargement with leptomeningeal involvement. OMF for 5 weeks was well tolerated, with 31% reduction of contrast-enhanced tumor volume and reduction in abnormal T2-weighted Fluid-Attenuated Inversion Recovery volume. Tumor shrinkage appeared to correlate with treatment dose. These findings suggest a powerful new noninvasive therapy for glioblastoma.

KW - compassionate use treatment

KW - contrast enhanced tumor

KW - magnetic resonance imaging

KW - oscillating magnetic fields

KW - radiation-type tumor necrosis 2

UR - http://www.scopus.com/inward/record.url?scp=85112670824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85112670824&partnerID=8YFLogxK

U2 - 10.3389/fonc.2021.708017

DO - 10.3389/fonc.2021.708017

M3 - Article

C2 - 34367992

AN - SCOPUS:85112670824

SN - 2234-943X

VL - 11

SP - 708017

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 708017

ER -

Case Report: End-Stage Recurrent Glioblastoma Treated With a New Noninvasive Non-Contact Oncomagnetic Device

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this